Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
Authors
Keywords
-
Journal
Journal of the American Heart Association
Volume 11, Issue 6, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-03-09
DOI
10.1161/jaha.121.022937
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk
- (2021) Brian Olshansky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
- (2021) Manan Pareek et al. Expert Opinion On Drug Safety
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
- (2021) Salim S. Virani et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization
- (2021) Ram D. Bhatt et al. PROGRESS IN CARDIOVASCULAR DISEASES
- A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
- (2021) Andrew Kosmopoulos et al. iScience
- Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry
- (2021) Fabien Picard et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability
- (2021) Samuel C.R. Sherratt et al. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
- (2020) Salim S. Virani et al. CIRCULATION
- Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
- (2020) R. Preston Mason et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
- (2020) Suzanne V. Arnold et al. CIRCULATION
- Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results
- (2020) Matthew J Budoff et al. CARDIOVASCULAR RESEARCH
- Applicability of the REDUCE‐IT trial to the FAST‐MI registry. Are the results of randomized trials relevant in routine clinical practice?
- (2020) Jean Ferrières et al. CLINICAL CARDIOLOGY
- The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
- (2020) Xiaowen Wang et al. Current Diabetes Reports
- Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery
- (2020) Andrew Kosmopoulos et al. CURRENT OPINION IN CARDIOLOGY
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
- (2020) Deepak L Bhatt EUROPEAN HEART JOURNAL SUPPLEMENTS
- REDUCE-IT INTERIM: Accumulation of Data Across Prespecified Interim Analyses to Final Results
- (2020) Brian Olshansky et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Reduction in Revascularization With Icosapent Ethyl
- (2020) Benjamin E. Peterson et al. CIRCULATION
- Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial
- (2020) Are Annesønn Kalstad et al. CIRCULATION
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
- (2019) Fabien Picard et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. CIRCULATION
- REDUCE-IT
- (2019) Deepak L Bhatt EUROPEAN HEART JOURNAL
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- Risk of Total Events With Icosapent Ethyl
- (2019) Christopher B. Granger et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States
- (2019) Deepak L. Bhatt et al. CIRCULATION
- Reply
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
- (2019) William E Boden et al. EUROPEAN HEART JOURNAL
- Newer Generation Ultra-Thin Strut Drug-Eluting Stents versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: A Meta-Analysis of Randomized Trials
- (2018) Sripal Bangalore et al. CIRCULATION
- Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
- (2018) Om P. Ganda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
- (2018) Theingi Aung et al. JAMA Cardiology
- 2018 ESC/EACTS Guidelines on myocardial revascularization
- (2018) Franz-Josef Neumann et al. EUROPEAN HEART JOURNAL
- Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
- (2018) Wenjun Fan et al. Journal of Clinical Lipidology
- Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
- (2018) JoAnn E. Manson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Total Cholesterol, Triglycerides, and Low-Density Lipoprotein in US Adults, 1999-2014
- (2017) Asher Rosinger et al. JAMA Cardiology
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started